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Abstract 
The development of antibodies against human G-protein-coupled receptors (GPCRs) 
has achieved limited success, and this has mainly been attributed to their low stability in 
a detergent-solubilized state. We herein described a method that can generally be 
applied to the selection of phage display libraries with human GPCRs reconstituted in 
liposomes. A key feature of this approach is the production of biotinylated 
proteoliposomes that can be immobilized on the surface of streptavidin-coupled 
microplates or paramagnetic beads and used as a binding target for antibodies. As an 
example, we isolated a single chain Fv fragment from an immune phage library that 
specifically binds to the human M2 muscarinic acetylcholine receptor with nanomolar 
affinity. The selected antibody fragment recognized the GPCR in both 
detergent-solubilized and in membrane-embedded forms, which suggested that it may 
be a potentially valuable tool for structural and functional studies of the GPCR. The use 
of proteoliposomes as immunogens and screening bait will facilitate the application of 
phage display to this difficult class of membrane proteins. 
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Introduction 
   G-protein-coupled receptors (GPCRs) comprise the largest class of 
signal-transducing receptors involved in a broad range of physiological processes 
ranging from cell cycle control to metabolism and the actions of hormones.(1,2) GPCR 
dysfunctions have been implicated in various pathological processes including 
cardiovascular, gastrointestinal, metabolic, neurodegenerative, psychiatric, and immune 
disorders as well as cancers. More than 30% of all clinically approved therapeutics 
currently target GPCRs.(3) As understanding of GPCR-associated disease pathologies 
increases, the need for new antibodies related to receptor characterization, purification, 
tissue localization, clinical diagnostics, and therapeutics is also growing. 
   However, raising antibodies against GPCRs is technically challenging for the 
following reasons: (i) the poor immunogenicity of GPCRs, which are largely buried in 
the membrane, (ii) the high degree of sequence homology between human and mouse 
genes, (iii) the low density of GPCRs in native cell membranes, (iv) the difficulties 
associated with obtaining sufficient amounts of the purified GPCRs expressed in 
heterologous hosts, and (v) most GPCRs in detergent-solubilized state are unstable and 
are likely to aggregate easily, such that denatured proteins and aggregation may cause 
non-specific binding during the selection of antibodies, thereby producing false 
positives. Furthermore, antibodies against GPCR-derived peptides rarely recognize 
native receptors and have adequate affinities or specificities, because the linear peptide 
does not necessarily replicate the loop in the complete GPCR structure. An approach 
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using purified human GPCRs in reconstituted liposomes as binding targets may 
overcome these problems. 
   Phage display technology offers an attractive strategy to facilitate the isolation of 
novel antibody fragments. The process is easier, faster, and less labor intensive than 
traditional hybridoma technology, in which significant expertise and time-consuming 
cell culture steps are needed to accomplish the desired antibody selection. Antibody 
phage libraries have been constructed under various settings, including naïve, synthetic, 
and immunized libraries.(4) Most high-quality naïve and synthetic libraries are 
proprietary or not yet commercially available, and it is also difficult to maintain highly 
complex diversity (109-1012 independent clones) during propagation in a routine 
laboratory.(5,6) In contrast, the construction and selection of immune libraries is a 
promising starting point because a smaller library size (5 x 105 - 1 x 106 clones) was 
previously shown to be sufficient for isolating high affinity binders.(7,8) Consecutive 
rounds of immunization and in vivo affinity maturation by the murine immune system is 
likely to result in a high frequency of antigen-specific B-cells, producing large amounts 
of antibodies and the corresponding mRNAs used for the generation of the focused 
library. 
   The M2 muscarinic acetylcholine receptor (M2 receptor) is a GPCR that has an 
essential role in the physiological control of cardiovascular function and many pivotal 
central processes, such as cognition and pain perception.(9) Due to its importance in 
medical and basic biological research, we selected the human M2 receptor as a model 
target in this study. We here demonstrated the isolation of a single chain Fv (scFv) 
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fragment against the human M2 receptor using a proteoliposome-targeted strategy, in 
both animal immunization and the subsequent selection of an immune phage display 
library. We also described simple and reliable methods used to characterize the binding 
properties of the selected antibody. 
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Materials and methods 
Proteoliposome antigen preparation 
   A variant of the human M2 receptor, M2-i3d, which lacks the central part of the 
third intracellular loop (ICL3) from Ser234 to Arg381 as well as the native 
glycosylation sites, was expressed in Sf9 insect cells, as described previously.(10) After 
solubilizing the membrane with digitonin/Na-cholate solution, M2-i3d bound to the 
high-affinity inverse agonist 3-quinuclidinyl-benzilate (QNB) was purified by using an 
aminobenztropine (ABT) affinity column and hydroxyapatite column, as described.(11) 
The eluate was concentrated with Amicon Ultra (Merck Millipore, Billerica, MA), and 
dialyzed against 20 mM HEPES-NaOH, pH 7.5, 200 mM NaCl, 5% glycerol, 0.05% 
n-dodecyl-β-D-maltopyranoside (DDM) (Anatrace, Maumee, OH), and 0.01% 
cholesterol hemisuccinate (CHS) (Sigma-Aldrich, St. Louis, MO). Proteoliposomes 
were prepared by removing the detergent from mixed lipid/detergent micelles using 
Bio-Beads SM-2 (Bio-Rad, Hercules, CA). Briefly, 1 mg of purified QNB-bound 
M2-i3d was added to a mixture of 4 mg of egg yolk phosphatidylcholine (egg PC; 
Avanti Polar Lipids, Alabaster, AL) and 1 mg of adjuvant Lipid A (Sigma-Aldrich) in 1 
mL of PBS containing 0.8% sodium cholate (Dojindo, Kumamoto, Japan). This was 
immediately followed by the addition of fresh Bio-Beads SM-2 and overnight 
incubation at 4oC. After removing the beads, the resultant suspensions were sonicated to 
produce small unilamellar vesicles. The reconstituted proteoliposome was stored at 
-80oC prior to use for immunization. 
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Immunization and antibody library construction 
   All animal experiments described in this study conformed to the guidelines outlined 
in the Guide for the Care and Use of Laboratory Animals of Japan and were approved 
by the University of Tokyo Animal Care Committee (approval no. RAC07101). M2 and 
M4 receptor double knockout mice were initially immunized with 0.1 mg of the 
proteoliposome antigen and 0.1 µg of pertussis toxin, followed by two or three booster 
injections of 0.1 mg of the proteoliposome antigen at two-week intervals. Immunized 
mice were sacrificed, and total RNA in the spleen was isolated using TRI reagent 
(Sigma-Aldrich) according to the manufacturer’s instructions. First-strand cDNA was 
synthesized from total RNA using an oligo (dT) primer and SuperScript III reverse 
transcriptase (Thermo Fisher Scientific, Waltham MA) in a standard procedure.(12) A 
combinatorial single-chain Fv (scFv) antibody library was generated by PCR 
amplification and the assembly of VL and VH immunoglobulin domains with an 18 
amino acid flexible linker, and was then cloned into the phagemid vector pComb3XSS, 
as described.(13)  
 
Proteoliposome-targeted panning of the combinatorial scFv library 
   Biotinylated proteoliposomes were used as the target for selection, and were 
prepared by the same method as that for the proteoliposome antigen described above, 
except that 0.5 mg/mL of the membrane protein was reconstituted with a mixture of 5 
mg/mL of egg PC and 25 µg/mL of 
1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(cap biotinyl) (16:0 biotinyl 
  8 
Cap-PE; Avanti Polar Lipids). To perform negative selection steps (i.e., subtractive 
panning on an otherwise equivalent system that lacks the target membrane protein), 
“empty” biotinylated liposomes were prepared with egg PC and 16:0 biotinyl Cap-PE. 
   All steps of the phage display selection were performed at 4oC or on ice. In the first 
selection cycle, 2 x 1013 phage particles displaying the scFv library (1 mL) were 
incubated for 1 h with “empty” biotinylated liposomes (200 µL; 50 µg/mL lipid in 
TBS-B buffer [10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% BSA]). Phage-empty 
liposome complexes were captured on 100 µL streptavidin-coated paramagnetic beads 
(10 mg/mL, Dynabeads MyOne Streptavidin T1, Thermo Fisher Scientific) for 1 h. The 
supernatant (1 mL) was collected and incubated with the biotinylated proteoliposome 
bait (200 µL; 50 µg/mL lipid and 5 µg/mL membrane protein in TBS-B) for 1 h. The 
phage-proteoliposome complexes were captured on the beads for 30 min. After washing 
the beads eight times with TBS-B, the phage particles were eluted with 100 µL of 100 
mM glycine-HCl, pH 2.5, for 10 min. Eluates were neutralized with 5 µL of 1 M 
Tris-HCl, pH 9.0, and used to infect 2 mL of exponentially growing E.coli XL-1 Blue 
cells (Agilent Technologies, Santa Clara, CA). After shaking for 1 h at 37oC, cells were 
plated on LB agar plates containing 100 µg/mL ampicillin and grown overnight at 37oC. 
The cells were scraped off the plates, and phage rescue was performed using the 
VCSM13 helper phage (Agilent Technologies) according to a standard method 
described previously.(14) 
   In the subsequent selection rounds, 1012 of the amplified phage particles were used 
as an input, and beads were washed 10 to 15 times with TBS-B. After the fourth round, 
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single clones were randomly picked and analyzed by a proteoliposome-targeted 
enzyme-linked immunosorbent assay (liposome ELISA; Fig. 1A) as described below, 
and the positive clones were sequenced. 
 
Liposome ELISA 
   E. coli XL-1 Blue, harboring pComb3XSS encoding a selected scFv, was grown 
overnight at 37oC. Two milliliters of SB (20 g of tryptone, 10 g of yeast extract, 5 g of 
NaCl per liter) containing 100 µg/mL ampicillin was inoculated with 50 µL of the 
overnight culture. After being incubated for 3 h at 37oC, expression was induced with 
IPTG (1 mM final concentration) and cells were grown at 30oC overnight with vigorous 
shaking. Cells were harvested, and the periplasmic extract was prepared by suspending 
the cells in an ice-cold high osmotic buffer (50 mM HEPES-NaOH, pH 7.5, 0.5 mM 
EDTA, 20% sucrose), followed by the addition of lysozyme (3 mg/mL final 
concentration) and incubation for 30 min at 37oC. The bacterial cells were removed by 
centrifugation at 15,000 x g for 10 min, and the scFv-containing supernatant was used 
for liposome ELISA, Biacore analysis, and epitope mapping. The scFv had a HA tag at 
the C-terminus. 
   Biotinylated proteoliposome bait (25 µL; 200 µg/mL lipid and 20 µg/mL membrane 
protein in TBS-B) or biotinylated empty liposomes (25 µL; 200 µg/mL lipid in TBS-B) 
were mixed with 100 µL of the E.coli periplasmic extract and incubated for 1 h on ice. 
The scFv-liposome complex was applied to a well of a Nunc Immobilizer Streptavidin 
plate (Thermo Fisher Scientific) and further incubated for 30 min on ice. After 
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extensive washing with TBS, bound scFv was detected with the anti-HA antibody POD 
conjugate (Roche Diagnostics, Basel, Switzerland; 1:1000 dilution in TBS-B, 1 h on 
ice) using ABTS (Sigma-Aldrich) as a substrate for POD. The absorbance of the color 
reaction was measured at 415 nm with a microplate reader (model 680, Bio-Rad). 
 
Binding kinetics measurements 
   Surface plasmon resonance (SPR) experiments were performed at 20oC using the 
Biacore T100 with series S streptavidin sensor chips (Series S sensor chip SA; GE 
Healthcare, Little Chalfont, UK) in the running buffer containing 20 mM 
HEPES-NaOH, pH 7.5, 200 mM NaCl, 5% glycerol, 0.05% DDM, and 0.01% CHS. 
Biotinylated anti-HA IgG (Rockland Immunochemicals, Gilbertsville, PA) was 
captured on the streptavidin surface (flow cells 1 and 2) by a 400-sec injection of 50 
μg/mL of the antibody at 10 μL/min. Crude scFv-containing E. coli periplasmic extracts 
with 12 mg/ml BSA and 12 mg/ml CM-dextran were subsequently injected (500 μL at a 
flow rate of 10 μL/min) over flow cell 2, in which the C-terminal HA-tagged scFvs 
were captured. QNB-bound M2-i3d at various concentrations was simultaneously 
passed over flow cells 1 and 2 at a flow rate of 30 μL/min. Association and dissociation 
times were 2 and 5 min, respectively, and regeneration consisted of a 30-sec injection of 
10 mM NaOH. Flow cell 1 was used as a reference surface. Data analysis was 
performed using BIAevaluation software (GE Healthcare). 
 
Epitope mapping 
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   The variants used for epitope mapping on M2-i3d are summarized in Table 1. 
Site-directed mutagenesis was conducted following a PCR-based protocol(15) or in vivo 
homologous recombination in Saccharomyces cerevisiae.(16) Different DNA fragments 
encoding M2-i3d and its variants were inserted into the vector pDDGFP-2,(17) and all 
the expression constructs were verified by DNA sequencing of the entire gene through 
the ligation junctions with the vector plasmid. The resultant constructs with a 
C-terminal fusion to GFP were overexpressed in S. cerevisiae, and membranes from 
small-scale (10 mL) cultures were prepared by the mechanical disruption of cells, which 
was achieved by shaking with glass beads, as described.(18) 
   A Nunc Maxisorp plate (Thermo Fisher Scientific) was coated with the membrane 
fractions containing an equivalent amount of M2-i3d and its variants in PBS, pH 7.4, at 
4oC overnight and blocked for 2 h with PBS-B (PBS, pH 7.4, containing 1% BSA) at 
4oC. The wells were incubated with 100 μL of HA-tagged scFv (10 μg/mL) in PBS-B 
for 1 h at 4oC. The bound HA-tagged scFv was detected as described above. 
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Results 
Library construction and selection 
   M2-i3d was used as a binding target throughout the present study because the 
central part of ICL3 in the human M2 receptor can be removed without impairing its 
ability to bind to agonists or activate G proteins.(19) Functional and folded proteins were 
specifically retrieved by ABT affinity column chromatography, and the purified M2-i3d 
used in proteoliposome reconstitution was in an inactive antagonist-bound 
conformation.  
   Among the five different muscarinic receptors, subtypes M1-M5, that have been 
cloned and characterized, the primary sequences of subtypes M2 and M4 are more 
homologous to each other than to other subtypes. In addition, the M2 and M4 receptors 
both couple efficiently to inhibit cyclic AMP,(20) suggesting similarities in the functional 
tertiary structures of the two subtypes. To abrogate the mechanisms of immune 
tolerance, two M2/M4 double knockout mice were immunized with 
M2-i3d-reconstituted liposomes to generate a library of murine immunoglobulin genes. 
To facilitate the immune response, adjuvant Lipid A was added as an ingredient to the 
proteoliposomes.(21) The sera obtained from mice became immunoreactive after the 
third or fourth immunization, as indicated by liposome ELISA (data not shown). 
Animals were sacrificed three days after the last immunization, and a scFv phage library 
was prepared. The library consisted of approximately 2.9 x 108 independent 
transformants. 
   Liposomes were immobilized via a biotinylated lipid on streptavidin-coupled 
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paramagnetic beads for phage panning. Four rounds of subtractive screening were 
performed using M2-i3d-proteoliposomes and empty liposomes devoid of M2-i3d, and 
phages that specifically bound to M2-i3d were retrieved and isolated. Ninety-six 
randomly chosen colonies were grown for the expression of their scFvs as soluble 
proteins. Crude periplasmic extracts were assessed using liposome ELISA, and 32 
extracts recognized the M2-i3d-proteoliposomes, but not the empty liposomes (Fig. 1B). 
Sequence analysis revealed only one scFv (Fig. 2). This scFv, designated as 18A107, 
was recloned for large scale expression, purification, and characterization. 
 
Binding kinetics 
   In SPR assays using Biacore, knowledge of the analyte concentration is a 
prerequisite for a detailed kinetic analysis. The purified GPCR was available in the 
present study, and using a crude E.coli periplasmic extract was sufficient for 
immobilizing the scFv on the sensor chip (e.g. an immobilized anti-HA antibody could 
also be used to capture the scFv with a HA tag at the C-terminus). Therefore, we 
devised a SPR assay in which purified M2-i3d was flowed over the immobilized scFvs 
in detergent-containing buffer (Fig. 3A).  
   Approximately 2000 RU of the biotinylated anti-HA antibody was immobilized on 
the surfaces of both flow cells 1 and 2. The scFv 18A107-containing crude periplasmic 
extract was injected over the predefined anti-HA immobilized sensor surface (flow cell 
2), which resulted in capture responses of approximately 150 RU. QNB-bound M2-i3d 
at concentrations of 0, 1, 2, 4, or 8 μg/mL was flowed over both flow cells. The kinetic 
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parameters for scFv18A107 with QNB-bound M2-i3d interactions were examined (Fig. 
3B). ScFv 18A107 showed high affinity to QNB-bound M2-i3d, KD = 1.0 nM, with  
kon = 1.5 x 105 M-1 s-1 and koff = 1.5 x 10-4 M-1 s-1. 
 
Epitope mapping 
   GPCRs have seven hydrophobic transmembrane helices and eight hydrophilic 
extramembrane regions, and anti-GPCR antibodies should bind to one or more of the 
extramembranous parts of GPCRs. To identify the epitope of scFv 18A107, each 
polypeptide segment located within the extracellular N-distal or intracellular C-distal 
domains or within the extra- or intracellular loops of M2-i3d was replaced with an 
arbitrary sequence to construct M2-Nr, M2-i1r, M2-o1r, M2-i2r, M2-o2r, M2-i3r, 
M2-o3r, and M2-Cr variants (Table 1). The expression of the resultant variants in S. 
cerevisiae was verified using the in-gel fluorescence of GFP as described(17) (data not 
shown). Aliquots of membrane fractions from these variants were directly immobilized 
on a MaxiSorp plate to perform an ELISA. ScFv 18A107 could recognize these variants, 
except for M2-i3r (Fig. 4A), suggesting that the epitope is located within the ICL3. 
   Detailed mapping of the epitope was conducted by alanine scanning mutagenesis 
within the ICL3 (Table 1). The amino acid substitutions, K219A, D220A, K222A, 
E223A, P224A, V225A and N227A resulted in the significant loss in the reactivity of 
scFv 18A107 (Fig. 4B). These results suggest that the side chain of the residue Lys221 
may not have contributed to the contact with scFv 18A107. Similar results were 
obtained in western-blotting experiments using SDS-denatured variant proteins (data 
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not shown). Thus, the epitope of scFv 18A107 could be defined as a peptide segment 
from Lys219 to Asn227 within the ICL3. This amino acid sequence does not exist in the 
other subtypes of muscarinic receptor (Fig. 4C), suggesting the high specificity of scFv 
18A107 on the M2 receptor.  
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Discussion 
   Human and mammalian GPCRs typically exhibit limited thermal stability once 
solubilized from the hydrophobic environment of the lipid bilayer by a detergent. Thus, 
the use of detergent-solubilized purified GPCRs as binding targets may lead to 
difficulties in maintaining the structural integrity of the GPCRs during the antibody 
selection process, and additional intricate strategies may be required to exclude false 
positives that recognize denatured GPCRs and their aggregates. In contrast, 
proteoliposome-targeted strategies have been used in anti-GPCR antibody screening via 
traditional hybridoma technology to successfully identify monoclonal antibodies against 
the human β2 adrenergic receptor (β2AR),(21,22) human orphan receptor RAI3 (also 
known as GPRC5A and RAIG-1),(23) and human adenosine A2A receptor (A2AR).(24) Fab 
fragments to the β2AR and A2AR were used as “crystallization chaperones”(25,26,27,28) to 
facilitate structural determination. 
   In this context, we utilized this proteoliposome-based strategy to devise an efficient 
method for anti-GPCR antibody production via phage display technology. Using the 
human M2 receptor as a model target, we succeeded in isolating of a high-affinity Fv 
fragment without further affinity maturation procedures. The whole process, from the 
immunization to the isolation of a single scFv, was completed within a short period of 
time (~10 weeks). To the best of our knowledge, this is the first study to demonstrate 
proteoliposome-targeted selection from a focused phage library built from immunized 
mice to isolate anti-GPCR antibodies. A similar approach has been used for the 
non-GPCR target, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
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(AMPA)-selective glutamate receptor GluRD,(29) which has large extramembranous 
hydrophilic domains unlike GPCRs. The procedures we established in this study may be 
useful for obtaining specific binders against human and mammalian GPCRs as well as 
other integral membrane proteins, especially those with low thermal stability. 
   The selected recombinant antibody fragment, Fv 18A107, could recognize the M2 
receptor in its detergent-solubilized form as well as that embedded in lipid bilayers. Due 
to this versatility and high affinity for the M2 receptor, this Fv can be used in various 
applications such as purification, immunoprecipitation or immunohistochemistry. 
Crystallization trials of M2-i3d complexed with Fv 18A107 were unsuccessful despite 
extensive screening, and this may have been because binding via a linear epitope does 
not stabilize one specific conformation of the M2 receptor. The epitope was located 
within the ICL3, which is known to be important for G-protein activation, and Fv 
18A107 may have prevented coupling of the M2 receptor to the G protein due to steric 
competition. The intracellular expression of scFv18A107 as an “intrabody”(30) may 
become a novel type of antagonist that inhibits signaling pathways downstream of 
G-protein activation. 
   In conclusion, we obtained a high-affinity recombinant scFv against the human M2 
receptor using proteoliposome-based technology with no further in vitro affinity 
maturation, which demonstrated that our approach can be used to generate binders to 
GPCRs and other integral membrane proteins. 
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Figure Legends 
 
Fig. 1. Proteoliposome-targeted ELISA (liposome ELISA) to test the binding of 
selected scFv clones after recursive phage display cycles. (A) Schematic representation 
of the experimental set-up. Biotinylated liposomes were captured in 
streptavidin-immobilized ELISA plates, and E.coli periplasmic extracts containing 
HA-tagged scFv for each clone were added. ScFv binding was detected with an anti-HA 
IgG-horseradish peroxidase conjugate. (B) Representative results of liposome ELISA. 
Solid bar: M2-i3d proteoliposome-targeted signal (binding); open bar: empty 
liposome-targeted signal (background). Clones marked with an asterisk were selected as 
positives and sequenced. 
 
Fig. 2. Nucleotide and amino acid deduced sequences of the scFv 18A107. The two SfiI 
restriction sites are represented in gray. The complementarity determining region (CDR) 
of the 18A107 antibody according to the Kabat numbering are underlined, and the 
18-residue linker between the light and heavy variable domains is represented in italic. 
 
Fig. 3. SPR analysis of the interaction between scFv 18A107 and detergent-solubilized 
M2-i3d. (A) Capture assay format used on the Biacore T100. Biotinylated anti-HA IgG 
(B-IgG) was immobilized in both flow cells 1 and 2 of a streptavidin (SA)-coated 
sensor chip. ScFvs (scFv-HA) were subsequently captured in flow cell 2. Flow cell 1 
was used as a reference surface. M2-i3d was passed over each flow cell simultaneously 
  25 
for 2 min, and the dissociation of M2-i3d in buffer was monitored for 5 min. (B) 
Sensorgrams (red) and fitted curves (black) for M2-i3d binding to captured scFv clone 
18A107. Detergent-solubilized QNB-bound M2-i3d was injected at 1, 2, 4, or 8 μg/mL, 
and the data were fit to a 1:1 model.  
 
Fig. 4. Mapping of the scFv 18A107 epitope on M2-i3d by crude membrane-targeted 
ELISA. (A) Identification of the critical hydrophilic domains of M2-i3d for binding to 
the scFv. To facilitate an interpretation, ELISA signals were background-subtracted and 
normalized to M2-i3d reactivity with the Fv. Results are the mean ± s.d. from three 
independent experiments. Mock: reactivity against the membrane fraction from yeast 
cells harboring the pDDGFP-2 empty vector. (B) Detailed mapping of the epitope. 
Immunoreactivities of the scFv against a series of M2-i3d variants containing 
alanine-scanning mutations within the ICL3 are shown. Error bars, s.d.; n=3. (C) 
Sequence alignments of a segment within the ICL3 of the five subtypes of human 
muscarinic acetylcholine receptors and mammalian counterparts of the subtype M2. The 
numbers correspond to the residue number used in the UniProt data P08172. The 
epitope recognized by Fv 18A107 is underlined. 
 
Table 1.  M2 receptor variants used for epitope mapping 
Variant Description Position of mutated 
segment or residuea 
Original sequence or residue  
in M2-i3d 
   Replaced sequence or residue 
M2-Nr Replacement in the extracellular 
N-distal domain 
2-22 DDSTDSSDNSLALTSPYKTFE TDDPLGGHTVWQ 
M2-i1r Replacement in the ICL1 51-59 NRHLQTVNN DKQLKTVDD 
M2-o1r Replacement in the ECL1 86-95 IGYWPLGPVV MNRWALGNLA 
M2-i2r Replacement in the ICL2 124-139 CVTKPLTYPVKRTTKM SITRPLTYRAKRSTKR 
M2-o2r Replacement in the ECL2 164-183 FIVGVRTVEDGECYIQFFSN YFVGKRTVPPGECFIQFLSE 




M2-o3r Replacement in the ECL3 414-419 APCIPN DSCVPK 
M2-Cr Replacement in the intracellular 
C-distal domain 







Alanine scanning mutagenesis 
within ICL3 
215 S A 
R216A 216 R A 
I217A 217 I A 
K218A 218 K A 
K219A 219 K A 
D220A 220 D A 
K221A 221 K A 
K222A 222 K A 
E223A 223 E A 
P224A 224 P A 
V225A 225 V A 
N227A 227 N A 
D229A 229 D A 
V231A 231 V A 
aAmino acid residues were numbered according to the same numbering scheme for full-length sequence of human muscarinic 








































































































































































































































































































































































































Fig. 1      Suharni et al.
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Fig. 2    Suharni et al.
  GTG GCC CAG GCG GCC GAG CTC GAT ATT GTG ATG ACA CAG TCT CAA AAA TTC ATG TCC ACA  <  60
  V   A   Q   A   A   E   L   D   I   V   M   T   Q   S   Q   K   F   M   S   T   
 
  TCA GTA GGA GAC AGG GTC AGC ATC ACC TGC AAG GCC AGT CAG AAT GTG GGT ACT GCT GTA  < 120
  S   V   G   D   R   V   S   I   T   C   K   A   S   Q   N   V   G   T   A   V  
  GCC TGG TAT CAA CAG AAA CCA GGA CAA TCT CCT AAA CTA CTG ATT TAC TCG GCA TCC AAT  < 180
  A   W   Y   Q   Q   K   P   G   Q   S   P   K   L   L   I   Y   S   A   S   N   
  CGG TAC ACT GGA GTC CCT GAT CGC TTC ACA GGC AGT GGA TCT GGG ACA GAT TTC ACT CTC  < 240
  R   Y   T   G   V   P   D   R   F   T   G   S   G   S   G   T   D   F   T   L   
  ACC ATC AGC AAT ATG CAG TCT GAA GAC CTG GCA GAT TAT TTC TGC CAG CAA TAT AGC AGC  < 300
  T   I   S   N   M   Q   S   E   D   L   A   D   Y   F   C   Q   Q   Y   S   S   
  TAT CCT CTC ACG TTC GGT GCT GGG ACA AAG TTG GAA ATA AAA TCC TCT GGT GGC GGT GGC  < 360
  Y   P   L   T   F   G   A   G   T   K   L   E   I   K   S   S   G   G   G   G   
  TCG GGC GGT GGT GGG GGT GGT TCC TCT AGA TCT TCC CTC GAG GTT CAG CTC CAG CAG TCT  < 420
  S   G   G   G   G   G   G   S   S   R   S   S   L   E   V   Q   L   Q   Q   S   
  GGG GCA GAA CTT GTG AAG CCA GGG GCC TCA GTC AAG TTG TCC TGC ACA GCT TCT GGC TTC  < 480
  G   A   E   L   V   K   P   G   A   S   V   K   L   S   C   T   A   S   G   F   
  AAC ATT AAA GAC CAC TTT TTG CAC TGG GTG AAG CAG AGG ACT GAA CAG GGC CTG GAG TGG  < 540
  N   I   K   D   H   F   L   H   W   V   K   Q   R   T   E   Q   G   L   E   W   
  ATT GGA AGG ATT GAT CCT GAG GAT GGT GAA ACT AAA TAT GCC CCG AAA TTC CAG GGC AAG  < 600
  I   G   R   I   D   P   E   D   G   E   T   K   Y   A   P   K   F   Q   G   K   
  GCC ACT ATT ACA GCA GAC ACA TCC TCC AAT ACA GCC TCC CTG CAG CTC AGC AGC CTG ACA  < 660
  A   T   I   T   A   D   T   S   S   N   T   A   S   L   Q   L   S   S   L   T   
  TCT GAG GAC ACT GCC GTC TAT TAT TGT GCT ATT ATA CGA GGG AGA AGT TAT TCT ATG GAC  < 720
  S   E   D   T   A   V   Y   Y   C   A   I   I   R   G   R   S   Y   S   M   D   
  TAC TGG GGT CAA GGA ACT TCA GTC ACC GTC TCC TCA GCC AAA ACG ACA CCC CCA TCT GTC  < 780
  Y   W   G   Q   G   T   S   V   T   V   S   S   A   K   T   T   P   P   S   V   
  ACT AGT GGC CAG GCC GGC CAG  < 801
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